Pharvaris (NASDAQ:PHVS) Stock Rating Upgraded by Wall Street Zen

Pharvaris (NASDAQ:PHVS) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts also recently issued reports about the stock. Oppenheimer increased their price target on shares of Pharvaris from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, December 4th. Morgan Stanley upped their target price on shares of Pharvaris from $37.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, December 4th. Guggenheim raised their price target on shares of Pharvaris from $32.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, December 4th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Wednesday, December 3rd. Finally, Leerink Partners set a $38.00 price objective on Pharvaris in a research note on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.56.

Pharvaris Stock Up 5.1%

Pharvaris stock opened at $26.42 on Friday. Pharvaris has a one year low of $11.51 and a one year high of $29.80. The business has a fifty day moving average price of $26.01 and a 200-day moving average price of $24.00.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.08. On average, research analysts predict that Pharvaris will post -2.71 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

Several hedge funds have recently added to or reduced their stakes in PHVS. TD Asset Management Inc increased its position in shares of Pharvaris by 27.4% during the 2nd quarter. TD Asset Management Inc now owns 99,510 shares of the company’s stock valued at $1,751,000 after purchasing an additional 21,388 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in Pharvaris in the second quarter worth approximately $57,000. Geode Capital Management LLC grew its position in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after acquiring an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. grew its position in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the last quarter. Finally, Legal & General Group Plc raised its stake in shares of Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.